D-PLEX NDA Under FDA Priority Review with PDUFA Goal Date of November 28, 2026; U.S. Commercial Launch Preparations Ongoing
Expanding D-PLEX Globally: MAA Submitted and Validated by the EMA and European Commercialization Rights to D-PLEX Regained
"PolyPid 2030" Growth Strategy Unveiled, Introducing PD01B, a New Kynatrix(TM)-Based Product Candidate for the Treatment of Diabetic Foot Infections
$30 Million Received from Azurity
Conference Call Scheduled for Today at 8:30 AM ET
PETACH TIKVA, Israel, Nov. 11, 2026 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) ("PolyPid" or the "Company"), an innovative biopharmaceutical company dedicated to improving patient outcomes by elevating treatment effectiveness, right where care begins, today provided a corporate update and reported financial results for the three and nine months ended September 30, 2026.
Recent Corporate Highlights:
D-PLEX Under U.S. Food and Drug Administration ("FDA") Priority Review; PolyPid and Azurity Preparing for Potential U.S. Launch:
-- The FDA is reviewing the New Drug Application ("NDA") for D-PLEX for the
prevention of surgical site infections ("SSIs") in patients undergoing
colorectal surgery under Priority Review, with a Prescription Drug User
Fee Act ("PDUFA") goal date of November 28, 2026. Labeling discussions
with the FDA are underway, and all scheduled FDA interactions are on
track and aligned with the PDUFA goal date.
-- Subject to approval, PolyPid and Azurity Pharmaceuticals ("Azurity") are
preparing for the U.S. commercial launch of D-PLEX in early 2027. Azurity
is building its U.S. commercial organization, with an existing hospital
footprint that reaches more than 1,700 leading U.S. hospitals and
academic centers.
-- A New Technology Add-on Payment ("NTAP") application for D-PLEX has been
submitted to the Centers for Medicare & Medicaid Services ("CMS"), with a
decision expected in August 2027. If granted, NTAP would provide
additional hospital reimbursement for D-PLEX in the inpatient setting.
-- PolyPid has received a total of $30 million in upfront and near-term
milestone payments from Azurity, comprising $15 million upon signing of
the agreement in July 2026 and an additional $15 million milestone
payment following FDA acceptance of the NDA, received subsequent to
September 30, 2026. PolyPid remains eligible for over $290 million in
additional regulatory, launch and sales-based milestone payments. In
addition, upon commercialization, PolyPid will receive a pre-negotiated
transfer price for each unit of D-PLEX it manufactures and supplies to
Azurity, as well as tiered royalties ranging from mid-teen to
mid-twenties percentages on sales in the U.S. and Canada.
Expanding D-PLEX Globally:
-- On September 14, 2026, PolyPid submitted its Marketing Authorization
Application ("MAA") for D-PLEX to the European Medicines Agency ("EMA")
under the Centralized Procedure, meeting its previously communicated
third quarter 2026 timeline. Subsequent to quarter end, the EMA validated
the MAA, initiating its formal review. A decision is expected in the
second half of 2027.
-- PolyPid and ADVANZ PHARMA mutually agreed to terminate their 2022
exclusive License, Distribution and Supply Agreement for D-PLEX in Europe,
and exclusive European commercialization rights to D-PLEX have reverted
to PolyPid.
-- The Company is in active discussions with potential commercial partners
in Europe.
"PolyPid 2030" Strategy and Expanded Kynatrix(TM) Pipeline:
-- Subsequent to quarter end, on October 28, 2026, PolyPid hosted its
"PolyPid 2030" virtual investor day and KOL event, outlining a long-term
growth strategy built on three levers: maximizing D-PLEX through the
Azurity partnership, including label expansion beyond colorectal surgery;
expanding D-PLEX into Europe and other territories through partnerships;
and building a Kynatrix-based pipeline.
-- Introduced PD01B, a new hyper-localized Kynatrix-based product candidate
for the treatment of moderate to severe diabetic foot infections
following wound debridement. PD01B is designed to deliver
high-concentration doxycycline in the wound for weeks and is expected to
be developed under its own NDA, separate from D-PLEX . PD01B leverages
the active ingredient, Kynatrix technology, manufacturing site and
processes, and preclinical and safety foundation established for D-PLEX .
PolyPid holds worldwide commercial rights to PD01B.
-- PolyPid's long-acting obesity program, PD03A, continues in early
preclinical development.
"With our PDUFA goal date fast approaching, this is a defining moment for PolyPid," said Dikla Czaczkes Akselbrad, Chief Executive Officer of PolyPid. "We have a committed partner in Azurity preparing to bring D-PLEX to surgeons and patients in the U.S., subject to approval, and we now hold full rights to D-PLEX in Europe. As D-PLEX moves toward commercialization, we are leveraging the Kynatrix technology to strengthen our pipeline. At our recent investor day, we presented how it can reach beyond surgical site infections, starting with PD01B in diabetic foot infections, a serious condition where systemic antibiotics often fall short. We are now focused on executing our PolyPid 2030 plan, and we look forward to sharing our progress."
Upcoming Expected Milestones:
-- PDUFA goal date for the D-PLEX NDA of November 28, 2026.
-- Initiation of FDA communications on label expansion of D-PLEX into
broader abdominal surgery in the fourth quarter of 2026.
-- Potential U.S. commercial launch of D-PLEX by Azurity in early 2027.
-- New Drug Submission for D-PLEX in Canada in 2027.
-- CMS decision on NTAP for D-PLEX in August 2027.
-- EMA decision on the D-PLEX MAA in the second half of 2027.
-- PD01B pre-Investigational New Drug ("IND") meeting with the FDA and
first-in-human study, both expected in the second half of 2027.
Financial Results for the Three Months Ended September 30, 2026
-- Research and development expenses for the three months ended September
30, 2026, were $6.5 million, compared to $5.3 million in the same
three-month period of 2025. The increase was primarily due to the ongoing
NDA-related activities and continued commercial readiness preparation.
-- General and administrative expenses for the three months ended September
30, 2026, were $1.5 million, compared to $1.8 million for the same period
of 2025. The decrease was primarily due to the decrease of non-cash
expenses related to performance-based options following the positive
Phase 3 SHIELD II topline results, which triggered the vesting of those
options.
-- Marketing and business development expenses for the three months ended
September 30, 2026, were $0.4 million, compared to $0.4 million for the
same period of 2025.
-- Other income for the three months ended September 30, 2026, was $2.5
million, reflecting the recognition of previously deferred revenue
following the termination of the ADVANZ agreement on September 30, 2026.
-- For the three months ended September 30, 2026, the Company had a net loss
of $5.8 million, or $(0.24) per share, compared to a net loss of $7.5
million, or $(0.37) per share, in the three-month period ended September
30, 2025.
Financial Results for the Nine Months Ended September 30, 2026
-- Research and development expenses for the nine months ended September 30,
2026, were $18.4 million, compared to $17.6 million in the same
nine-month period of 2025. The increase was primarily due to the ongoing
NDA-related activities and continued commercial readiness preparation.
-- General and administrative expenses for the nine months ended September
30, 2026, were $4.4 million, compared to $5.4 million for the same period
of 2025. The decrease was primarily due to the decrease of non-cash
performance-based options vesting expenses.
-- Marketing and business development expenses for the nine months ended
September 30, 2026, were $1.3 million, compared to $1.4 million for the
same period of 2025.
-- Other income for the nine months ended September 30, 2026, was $2.5
million, as described above.
-- For the nine months ended September 30, 2026, the Company had a net loss
of $21.3 million, or $(0.94) per share, compared to a net loss of $25.7
million, or $(1.72) per share, in the nine-month period ended September
30, 2025.
Balance Sheet Highlights
-- As of September 30, 2026, the Company had cash, cash equivalents and
short-term deposits of $15.5 million, compared to $12.9 million on
December 31, 2025. Following the end of the quarter, the Company received
an additional $15 million milestone payment from its U.S. partner,
Azurity, following the FDA's acceptance of the D-PLEX NDA, further
strengthening its balance sheet.
-- The Company believes that its current cash position, together with its
expected proceeds from its commercialization agreement with Azurity, as
well as future potential proceeds, will be sufficient to fund operations
into 2028 and through several significant upcoming potential milestones.
Conference Call Dial-In & Webcast Information:
Date: Wednesday, November 11, 2026
Time: 8:30 AM Eastern Time
Conference Call: https://register-conf.media-server.com/register/B
Ia693ec3496b1413b8682b952b2ff9e10
Webcast: https://edge.media-server.com/mmc/p/rsj3o3mw
About PolyPid
PolyPid Ltd. (Nasdaq: PYPD) is an innovative biopharmaceutical company dedicated to elevating treatment effectiveness, right where care begins. The Company develops long-acting, controlled-release drugs designed to deliver therapy precisely at the site of care, addressing critical unmet medical needs across a wide and diverse pipeline spanning surgical care, metabolic diseases, and beyond. PolyPid's lead product, D-PLEX , successfully met its primary and all key secondary endpoints in the landmark Phase 3 SHIELD II trial for the prevention of surgical site infections. Guided by a commitment to precision and innovation, PolyPid is redefining how therapies perform and raise the standard of patient care. For additional Company information, please visit http://www.polypid.com and follow us on Twitter (X) and LinkedIn.
Forward-looking Statements
This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act and other securities laws. Words such as "expects," "anticipates," "intends," "plans," "believes," "seeks," "estimates" and similar expressions or variations of such words are intended to identify forward-looking statements. For example, the Company is using forward-looking statements when it discusses the FDA's review of the D-PLEX NDA, including the PDUFA goal date, the outcome and timing of such review, the Company's ongoing labeling discussions with the FDA, and the potential approval of D-PLEX ; the anticipated timing of a potential U.S. commercial launch of D-PLEX by Azurity and Azurity's launch preparations; potential reimbursement for D-PLEX , including the anticipated timing of a CMS decision on NTAP; the timing, receipt and amount of regulatory, launch and sales-based milestone payments, transfer price payments and royalties under the Company's agreement with Azurity; the potential label expansion of D-PLEX , including the planned initiation of communications with the FDA and the anticipated timing of potential label expansion; the EMA's review of the MAA for D-PLEX , the anticipated timing of a decision and a potential EU launch; the Company's plans for the commercialization of D-PLEX in Europe and other territories, including potential partnerships; the planned New Drug Submission for D-PLEX in Canada; the Company's "PolyPid 2030" growth strategy; the design, development plan, regulatory pathway and anticipated timing of a pre-IND meeting and first-in-human study for PD01B, and its potential benefits; the Company's plans to advance Kynatrix technology through additional pipeline programs, including its long-acting obesity program, PD03A, and the anticipated development and potential applications of such programs; the Company's belief that its current cash position, together with its expected proceeds from its commercialization agreement with Azurity, as well as future potential proceeds, will be sufficient to fund operations into 2028 and through several significant upcoming potential milestones; and the therapeutic and commercial potential of D-PLEX . Forward-looking statements are not historical facts, and are based upon management's current expectations, beliefs and projections, many of which, by their nature, are inherently uncertain. Such expectations, beliefs and projections are expressed in good faith. However, there can be no assurance that management's expectations, beliefs and projections will be achieved, and actual results may differ materially from what is expressed in or indicated by the forward-looking statements. Forward-looking statements are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in the forward-looking statements. For a more detailed description of the risks and uncertainties affecting the Company, reference is made to the Company's reports filed from time to time with the Securities and Exchange Commission, including, but not limited to, the risks detailed in the Company's Annual Report on Form 20-F filed on February 25, 2026. Forward-looking statements speak only as of the date the statements are made. The Company assumes no obligation to update forward-looking statements to reflect actual results, subsequent events or circumstances, changes in assumptions or changes in other factors affecting forward-looking information except to the extent required by applicable securities laws. If the Company does update one or more forward-looking statements, no inference should be drawn that the Company will make additional updates with respect thereto or with respect to other forward-looking statements. References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. PolyPid is not responsible for the contents of third-party websites.
Company Contact:
PolyPid Ltd.
Ori Warshavsky
908-858-5995
IR@Polypid.com
Investor Relations Contact:
Arx Investor Relations
North American Equities Desk
polypid@arxhq.com
INTERIM CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED)
--------------------------------------------------------------------------
U.S. dollars in thousands
September 30, December 31,
2026 2025
--------------- ----------------
ASSETS
CURRENT ASSETS:
Cash and cash equivalents $ 5,414 $ 6,402
Restricted deposits 201 193
Short-term deposits 10,085 6,531
Accounts receivable 15,000 -
Pre-launch inventories 1,567 1,106
Prepaid expenses and other current
assets 901 995
----------- ----------
Total current assets 33,168 15,227
--------------------------------------- ----------- ----------
NON-CURRENT ASSETS:
Property and equipment, net 4,553 5,094
Operating lease right-of-use assets 1,181 1,675
Long-term deposits 318 311
Other long-term asset 900 -
----------- ----------
Total non-current assets 6,952 7,080
--------------------------------------- ----------- ----------
Total assets $ 40,120 $ 22,307
--------------------------------------- =========== ==========
INTERIM CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED)
--------------------------------------------------------------------------
U.S. dollars in thousands (except share and per share
data)
September 30, December 31,
2026 2025
--------------- ----------------
LIABILITIES AND SHAREHOLDERS'
EQUITY
CURRENT LIABILITIES:
Trade payables $ 1,573 $ 2,856
Accrued expenses and other current
liabilities 2,981 2,734
Current maturities of long-term debt - 988
Current maturities of operating
lease liabilities 1,030 1,161
---------- ---------
Total current liabilities 5,584 7,739
--------------------------------------- ---------- ---------
NON-CURRENT LIABILITIES:
Deferred revenues 30,000 2,548
Long-term operating lease
liabilities 227 647
Long-term other liabilities 408 400
---------- ---------
Total non-current liabilities 30,635 3,595
--------------------------------------- ---------- ---------
COMMITMENTS AND CONTINGENT LIABILITIES
SHAREHOLDERS' EQUITY:
Ordinary shares, no par value -
Authorized: 107,800,000 shares at
September 30, 2026 and December 31,
2025; Issued and outstanding:
21,125,704 and 18,204,002 shares at
September 30, 2026 and December 31,
2025, respectively - -
Additional paid-in capital 326,732 312,473
Accumulated deficit (322,831) (301,500)
---------- ---------
Total shareholders' equity 3,901 10,973
--------------------------------------- ---------- ---------
Total liabilities and shareholders'
equity $ 40,120 $ 22,307
--------------------------------------- ========== =========
INTERIM CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(UNAUDITED)
---------------------------------------------------------------------------
U.S. dollars in thousands (except share and per share
data)
Nine Months Ended Three Months Ended
September 30, September 30,
------------------------- ----------------------------
2026 2025 2026 2025
------------ ----------- ------------ --------------
Operating
expenses:
Research and
development $ 18,404 $ 17,589 $ 6,523 $ 5,257
Marketing and
business
development 1,291 1,421 418 432
General and
administrative 4,384 5,427 1,529 1,766
Other income (2,548) - (2,548) -
---------- ---------- ---------- ----------
Operating loss 21,531 24,437 5,922 7,455
Loss on
extinguishment of
debt - 512 - -
Financial expense
(income), net (208) 661 (170) (26)
---------- ---------- ---------- ----------
Loss before income
tax 21,323 25,610 5,752 7,429
Income tax
expenses 8 86 2 22
---------- ---------- ---------- ----------
Net loss $ 21,331 $ 25,696 $ 5,754 $ 7,451
========== ========== ========== ==========
Basic and diluted
loss per ordinary
share $ 0.94 $ 1.72 $ 0.24 $ 0.37
========== ========== ========== ==========
Weighted average
number of
ordinary shares
used in computing
basic and diluted
loss per share 22,751,434 14,920,521 23,677,711 20,054,071
========== ========== ========== ==========
Comments